Clinical Trials Directory

Trials / Completed

CompletedNCT01153009

Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Duloxetine-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (15 and 20 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
614 (actual)
Sponsor
Takeda · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of vortioxetine, once daily (QD), compared with placebo in adults with major depressive disorder.

Detailed description

The drug that was tested in this study is called Vortioxetine. Vortioxetine is being tested to treat depression in adults who have major depressive disorder (MDD). This study looked at MDD relief in people who took varying dosages of vortioxetine. The study enrolled 614 patients. Participants were randomly assigned (by chance, like flipping a coin) to one of the four treatment groups-which remained undisclosed to the patient and study doctor during the study (unless there was an urgent medical need): * Vortioxetine 15 mg * Vortioxetine 20 mg * Duloxetine 60 mg * Placebo (dummy inactive capsule) - this was a capsule that looked like the study drug but had no active ingredient. All participants were asked to take one capsule at the same time each day throughout the study. This multi-center trial was conducted in the United States. The overall time to participate in this study was up to 13 weeks. Participants made 9 visits to the clinic, and were contacted by telephone 4 weeks after the last dose of study drug for a follow-up assessment.

Conditions

Interventions

TypeNameDescription
DRUGVortioxetineEncapsulated vortioxetine immediate release tablets
DRUGDuloxetineOverencapsulated duloxetine delayed-release capsules
DRUGPlaceboPlacebo-matching capsules

Timeline

Start date
2010-06-01
Primary completion
2012-03-01
Completion
2012-03-01
First posted
2010-06-29
Last updated
2013-12-18
Results posted
2013-12-18

Locations

56 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01153009. Inclusion in this directory is not an endorsement.